Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 3:16:1-7.
doi: 10.2147/IJWH.S444258. eCollection 2024.

The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening

Rajnish Nagarkar  1 , Mamillapalli Gopichand  2 , Suparna Kanti Pal  3 , Ankur Gupta  4   5 , Najmuddin Mohd Saquib  4   5 , Ganga Sagar  4 , Kanury V S Rao  4   5 , Zaved Siddiqui  4   5 , Imliwati Longkumer  6
Affiliations

The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening

Rajnish Nagarkar et al. Int J Womens Health. .

Abstract

We evaluated the potential relevance of our multi-cancer detection test, OncoVeryx-F, for ovarian cancer screening. For this, we compared its accuracy with that of CA125-based screening. We demonstrate here that, in contrast to CA125-based detection, OncoVeryx-F detected ovarian cancer with very high sensitivity and specificity. Importantly here, Stage I cancers too could be detected with an accuracy of >98%. Furthermore, again unlike CA 125, the detection accuracy of OncoVeryx-F remained comparable in both Caucasian and South Asian/Indian women. Thus, the robustness and accuracy of OncoVeryx-F, particularly for early-stage detection, underscores its potential utility for ovarian cancer screening.

Keywords: CA 125; LC-MS/MS; NoC; Oncoveryx-F; OvC.

PubMed Disclaimer

Conflict of interest statement

AG, GS, ZS, NMS and KVSR are fulltime employees of PredOmix Technologies Private Limited. KVSR is a cofounder and owns stock in both PredOmix Technologies Private Limited and PredOmix Health Sciences Pte. Ltd. AG, ZS, and NMS own stock in PredOmix Health Sciences Pte. Ltd. SP is one of the Principal Investigators in studies sponsored by Predomix Technologies. The work described in this report is included in an Indian Provisional Patent Application filing. Application No. 202311002270. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
STARD diagram to report flow of participants through the study.
Figure 2
Figure 2
A comparison of the efficacies of OncoVeryx-F and CA 125-based testing for OvC detection. (A) Shows the confusion matrix generated from the y-scores estimated by OncoVeryx-F for the individual OvC and NoC samples. The sensitivity obtained was 98.6% (96.41, 100) at 95% CI, at a specificity of 99.03% (97.08, 100) at 95% CI, and the accuracy was 98.85% (97.32, 100) at 95% CI. (B) Shows the corresponding matrix obtained when OvC versus NoC discrimination was derived on the basis of the CA 125 cut-off level of 35 U/mL. The sensitivity and specificity obtained in each case is also given here.
Figure 3
Figure 3
Ethnicity-dependence of the performance of CA 125 and OncoVeryx-F for OvC detection. Shows the distribution of CA 125 concentrations in samples from the OvC and NoC groups in both Caucasian and South Asian/Indian women.
Figure 4
Figure 4
Comparative efficacy of Stage I OvC detection by OncoVeryx-F and CA 125. Shown here are the confusion matrices obtained for detection of Stage I OvC samples using either OncoVeryx-F (A) or CA 125 (B) as the test system.
See this image and copyright information in PMC

References

    1. Hennesy BT, Coleman RL, Markman M. Ovarian Cancer. Lancet. 2009;374:1371–1382. - PubMed
    1. Zeppernick F, Meinhold-Heerlein I, Meinhold-Heerlien AI. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obs. 2014;290:839–842. doi:10.1007/s00404-014-3364-8 - DOI - PubMed
    1. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480.e1–480.e8. doi:10.1016/j.ajog.2011.06.049 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. doi:10.3322/caac.21660 - DOI - PubMed
    1. Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and ovarian cancer: a comprehensive review. Cancers. 2020;12(12):3730. doi:10.3390/cancers12123730 - DOI - PMC - PubMed